Piperlongumine Senolytic Therapy for Selective Cell Depletion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is no existing drug that can selectively deplete senescent cells, which accumulate with aging and contribute to various diseases such as COPD, osteoarthritis, atherosclerosis, and neurodegenerative diseases, leading to tissue degeneration and inflammation.
Innovation Solution
Piperlongumine (PL) and its derivatives are used to selectively kill senescent cells by increasing reactive oxygen species, offering a potential senolytic therapy to deplete these cells, which can be formulated into pharmaceutical compositions with additional agents for enhanced efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-aging approaches are used, then general health maintenance is improved, but selective depletion of senescent cells cannot be achieved
Solution Approach 1:
The patent applies local quality by exploiting the specific biochemical characteristics of senescent cells (elevated ROS levels, altered redox state) to selectively target them with piperlongumine, while leaving healthy cells unaffected. This is achieved through the differential redox sensitivity between senescent and healthy cells, allowing the drug to act locally on the pathological cell population.
Solution Approach 2:
The invention utilizes parameter changes by monitoring and exploiting the redox state parameter that distinguishes senescent cells from healthy cells. Piperlongumine selectively induces ROS-mediated cell death in senescent cells by altering their redox balance, while healthy cells maintain their redox homeostasis and survive the treatment.
2Object-affected harmful factors
If senescent cells accumulate with aging, then tissue degeneration and inflammation worsen, but no existing drug can selectively deplete them
Solution Approach 1:
The patent converts the harmful elevated ROS levels in senescent cells into a beneficial therapeutic target. By using piperlongumine to selectively induce ROS-mediated cell death in senescent cells, the invention transforms the pathological oxidative stress into a selective killing mechanism that eliminates harmful cells while sparing healthy ones.
3Reliability
If piperlongumine is used to kill senescent cells, then selective depletion is achieved, but potential off-target effects on healthy cells must be managed
Solution Approach 1:
The patent applies preliminary action by using combination therapies where protective agents are administered before or with piperlongumine to pre-shield healthy cells from potential ROS-mediated damage. This preliminary protection allows the therapeutic to selectively kill senescent cells while minimizing off-target effects on healthy tissues.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
PL and its derivatives effectively target and eliminate senescent cells, potentially delaying age-related pathologies and disorders, providing a novel anti-aging strategy to promote healthier aging.
Implementation Method 1
Piperlongumine (PL) selectively kills senescent cells by increasing reactive oxygen species
Data Source
AI summary
The present disclosure provides compositions and methods for selectively killing senescent cells, wherein the composition comprises piperlongumine (PL) or derivative thereof. The selective killing of senescent cells may delay aging and/or treat age-related disorders.